GlassScriptPhysician profile
Christy Rainey
NPI 1790999100
$328,299.19
in general payments reported to CMS, 2019-2025
50 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135K · 2020: $30K · 2021: $23K · 2022: $46K · 2023: $41K · 2024: $29K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $16K · Consulting Fee: $4,800 · Travel and Lodging: $3,033 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,815.00 |
| Food and Beverage | $16,142.07 |
| Consulting Fee | $4,800.00 |
| Travel and Lodging | $3,033.15 |
| Education | $266.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171,440.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $82,801.46 | 2019-2025 | |
| Incyte Corporation | $27,854.44 | 2021-2025 | Opzelura, Opzelura |
| Almirall LLC | $10,807.76 | 2019-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $5,507.42 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $4,972.49 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $3,645.05 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $3,230.39 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,797.89 | 2019-2025 | Jublia, Cabtreo, Duobrii |
| Regeneron Healthcare Solutions, INC. | $1,717.23 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,653.62 | 2020-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,286.77 | 2019-2025 | |
| Lilly USA, LLC | $1,263.05 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $1,217.57 | 2022-2025 | Sotyktu |
| Pfizer INC. | $886.75 | 2019-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $778.86 | 2019 | |
| Arcutis Biotherapeutics, INC. | $676.77 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $668.66 | 2020-2021 | |
| Biofrontera INC. | $618.47 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Scientific Affairs, LLC | $581.56 | 2019-2025 | Tremfya |
| Amgen INC. | $569.45 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $527.90 | 2019-2025 | Adbry |
| Organon LLC | $486.74 | 2025 | Vtama, Nexplanon |
| Journey Medical Corporation | $382.23 | 2019-2024 | |
| Revance Therapeutics, INC. | $358.23 | 2024-2025 | Daxxify |
| Mayne Pharma Commercial LLC | $194.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.75 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $159.98 | 2020-2021 | |
| Genentech USA, INC. | $155.49 | 2019-2023 | Xolair |
| Verrica Pharmaceuticals INC. | $149.63 | 2024 | Ycanth |
| Merz North America, INC. | $146.14 | 2019 | |
| Prugen, INC. Pharmaceuticals | $62.47 | 2019 | |
| Tactile Systems Technology INC | $55.41 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Organogenesis INC. | $51.44 | 2024-2025 | Via Matrix |
| Encore Dermatology INC. | $49.83 | 2019-2020 | |
| Celgene Corporation | $46.90 | 2019 | |
| Epi Health, LLC | $42.10 | 2021-2022 | |
| Botanix Sb INC | $38.72 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $32.43 | 2024 | Clindacin Etz |
| Allergan, INC. | $32.26 | 2019-2021 | |
| Dermira, INC. | $30.15 | 2019-2020 | |
| Krystal Biotech INC | $19.98 | 2023 | Vyjuvek |
| Paratek Pharmaceuticals, INC. | $19.96 | 2022 | |
| Mylan Institutional INC. | $19.95 | 2023 | Hulio |
| Sandoz INC. | $19.74 | 2024 | Hyrimoz |
| Nabriva Therapeutics, Plc | $19.07 | 2022 | |
| Mission Pharmacal Company | $17.06 | 2019 | |
| Medline Industries LP | $15.32 | 2024 | |
| Lnhc, INC | $14.94 | 2025 | Zelsuvmi |
| Solta Medical, A Division of Bausch Health US, LLC | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Rainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.